Published: 4 December 2025
Publications
Quarterly summary of recent safety communications
Published: 4 December 2025
Prescriber Update 46(4): 60
December 2025
The table below is a summary of recent safety communications for
healthcare professionals and consumers. Click on a specific topic to
go to the communication.
| Date |
Communication |
Topic |
| 11/11/2025 |
Monitoring |
Further Update - Estradot (estradiol) transdermal patches: reports
of quality and efficacy |
| 04/11/2025 |
Monitoring |
Update - Estradot (estradiol) transdermal patches: reports of
quality and efficacy |
| 22/10/2025 |
Dear Healthcare Professional Letter |
Recent complaints for Estradot transdermal patches (25, 50,
75 and 100 mcg/24 hrs) (PDF, 3 pages, 451 KB) |
| 22/10/2025 |
Monitoring |
Estradot (estradiol) transdermal patches: reports of quality
and efficacy |
| 13/10/2025 |
Dear Healthcare Professional Letter |
Paxlovid (nirmatrelvir/ritonavir) treatment in patients with
severe renal impairment (PDF, 5 pages, 322 KB) |
| 26/09/2025 |
News article |
Ministry of Health: Paracetamol use in pregnancy |
| 24/09/2025 |
Dear Healthcare Professional Letter |
Risperdal: Discontinuation of Risperdal (risperidone) tablets
across all strengths as of 15 December 2025 (PDF, 3 pages,
213 KB) |
| 23/09/2025 |
Alert |
Topiramate:
New measures and advice to prevent exposure during pregnancy
|
| 22/09/2025 |
Dear Healthcare Professional Letter |
Ribomustin: Discontinuation of Ribomustin (bendamustine hydrochloride)
25mg & 100mg powder for infusion as of 30 November 2025
(PDF, 2 pages, 216 KB) |
| 17/09/2025 |
Dear Healthcare Professional Letter |
Epilim:
Updated safety information for valproate: Risk in pregnancy
and women of childbearing potential – lower birth weight following
in utero exposure to valproate (PDF, 2 pages, 167 KB)
|
| 15/09/2025 |
Dear Healthcare Professional Letter |
Lenalidomide Viatris (lenalidomide) capsules: NZ-specific cartons
(PDF, 2 pages, 379 KB) |
| 12/09/2025 |
Dear Healthcare Professional Letter |
Polivy: Infusion site extravasation is a new identified risk
for Polivy (polatuzumab vedotin) (PDF, 3 pages, 169 KB)
|
| 08/09/2025 |
Dear Healthcare Professional Letter |
Tegretol
(carbamazepine) liquid: limitation of use in neonates (PDF,
1 page, 156 KB) |
Note that sponsors write Dear Healthcare Professional Letters and distribute
them to relevant healthcare professionals. Medsafe publishes copies
of these letters on the Medsafe
website.
